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9-Deazaguanine 9-DG, 1-methyl-9-deazaguanine AG-19-K1 and 1,7-dimethyl-9-deazaguanine
AG-3 were synthesized and their antiproliferative activity against five leukemia and four solid
tumor cell lines as well as inhibitory properties vs. calf spleen purine nucleoside phosphorylase
(PNP) were tested. Synthesis of 9-DG involves reaction of 2-amino-6-methyl-5-nitropyrimi-
din-4(3H)-one (2) with DMF-dimethylacetal (amount ratio, n(2) / n(DMF-dimethylacetal) =
1:2.5) and use of the benzyloxymethyl group to protect the N-3 position of 2-(N-dimethylami-
nomethylene)amino-6-methyl-5-nitropyrimidin-4(3H)-one (4). Reaction of 2 with DMF-dimethyl-
acetal (amount ratio, n(2) / n(DMF-dimethylacetal) = 1:6) gave the N-3 methyl substituted inter-
mediate 3. Dithionite reduction of this product afforded N-methyl derivatives AG-19-K1 and
AG-3. AG-19-K1 and AG-3 were inactive vs. calf spleen PNP at a concentration of 75 mmol dm–3.
Cytotoxic effects of 9-deazaguanine derivatives on cell growth were determined by the MTT
assay. Investigated derivatives showed moderate antiproliferative activity towards examined tu-
mor cells. At a concentration of 10–3 mol dm–3, AG-19-K1 inhibited the growth of JURKAT,
K562 and AGS cells by approximately 80 %. At the same concentration, AG-3 and 9-DG inhi-
bited cell proliferation by 40-50 % of all tested lines, except MOLT-4 and HL-60. The PNP
gene expression was changed in treated leukemia cells after exposure to AG-19-K1 and 9-DG
in a time-dependent manner.
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INTRODUCTION
Cancer encompasses many disease states generally cha-
racterized by abnormally proliferating cells and is a major
and often fatal disease. Chemotherapy is used in attempts
to cure or palliate diseases. However, no fundamental
trait has been associated with the wide array of cancers
known today that would permit an effective, uniform
and successful response to this disease. Scientific studies
can be broadly separated into those aimed at improving
the therapeutic index of currently available compounds
and those discovering new agents or approaches.1 One
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approach is to design novel compounds that could act as
antimetabolites and be able to reduce the activity of en-
zymes important to tumor cells’ metabolism. Purine nu-
cleoside phosphorylase (PNP) is an ubiquitous enzyme
of purine metabolism with a function in the salvage path-
way, enabling cells to utilize purine bases recovered from
metabolized purine ribo- and deoxyribo-nucleosides to
synthesized purine nucleotides.2 Biological importance
of PNP is well known but the kinetic mechanism seems
to be relatively complicated3 and the molecular mecha-
nism of catalysis has not been fully characterized.2,4–6 PNP
catalytic activity is increased in a number of leukemia cells
and colon carcinoma tissues.7,8 PNP is crucial for the in-
tegrity of the immune system, since PNP deficiency in
humans leads to defective T-cell response.2 Hence, po-
tent PNP inhibitors that would be able to cause effects
similar to PNP deficiency are expected to be useful in
treatment of some autoimmune diseases, other T-cell pro-
liferative disorders and also tumors of T-cells.2,9
Mammalian PNP is a trimeric molecule and contains
three active sites for ligands binding.2 The most potent
inhibitors of PNP, including transition state analogue in-
hibitors immucillins, are nucleosides and acyclonucleo-
sides, in which the carbon atom is substituted for the ni-
trogen atom at position nine of guanine base, resulting in
9-deazaguanine (9-DG) aglycone.2,10 Such inhibitors, es-
pecially immucillins, are able to significantly block PNP
activity.2,11 However, there is still need for alternative
potent PNP inhibitors and structure-activity relationship
studies show that such analogues should contain 9-DG
instead of the natural purine ring system, since such ana-
logues, having a hydrogen bond donor at position N(9)
of the base, are able to form a strong hydrogen bond with
PNP.2 To have easy access to such 9-deaza-derivatives,
we needed an efficient way of synthesizing 9-deazagua-
nine, so that we could introduce a variety of side chains
at position 9 of the base in a region-specific manner. We
therefore explored the synthesis of 9-DG according to the
literature procedures and, in addition to 9-DG, we also
isolated N-methyl derivatives of 9-deazaguanine: 1-meth-
yl-9-deazaguanine AG-19-K1 and 1,7-dimethyl-9-deaza-
guanine AG-3.
During the course of our attempts to synthesize new
nucleoside inhibitors of mammalian PNP, we realized that
9-deazaguanine itself was not characterized as a PNP in-
hibitor. This study was therefore also designed so as to
characterize inhibition properties vs. mammalian PNP of
9-deazaguanine and some of its derivatives, to explore
their effects on cell proliferation and influence on PNP
gene expression of the tumor cell lines tested.
EXPERIMENTAL
Chemistry in General
Solvents were distilled from appropriate drying agents shortly
before use. TLC was carried out on DC-plastikfolien Kiselgel
60 F254. Melting points were determined on a Kofler hot-
stage apparatus and were uncorrected. UV spectra (ëmax/nm,
log å/dm3 mol–1 cm–1) were taken on a Philips PU8700
UV/Vis spectrophotometer and on an Uvikon 930 (Kontron,
Austria) spectrophotometer fitted with a thermostatically
controlled cell compartment. The latter apparatus was also
used for kinetic measurements with spectrophotometric de-
tection of enzyme activity (see below). IR spectra (nmax/cm–1)
were obtained for KBr pellets on a Perkin-Elmer 297 spec-
trophotometer. The 1H and 13C NMR spectra were recorded
on a Varian Gemini 300 spectrometer, operating at 75.46 MHz
for the 13C nucleus. Samples were dissolved in DMSO-d6
and measured at 20 °C in 5 mm NMR tubes. Sample con-
centrations were 0.1 mol dm–3 for 1H and 0.2 mol dm–3 for
13C measurements. Chemical shifts (d/ppm) were referred
to DMSO. Digital resolution was 0.3 Hz per point in 1H
and 0.5 Hz per point in 13C NMR one-dimensional spectra.
The applied techniques were standard 1H and 13C with
broadband proton decoupling, 13C gated decoupling, COSY
and NOESY. Waltz-16 modulation was used for proton de-
coupling. COSY spectra were recorded in the magnitude
mode with 1024 points in F2 dimension and 256 increments
in F1 dimension, zero-filled to 1024 points. Increments were
measured with 16 scans, 4500 Hz spectral width and a re-
laxation delay of 0.8 s. The corresponding digital resolution
was 8.9 Hz per point and 17.6 Hz per point in F2 and F1
dimensions, respectively. NOESY spectra were recorded in
a phase-sensitive mode and at mixing times of 0.45-0.80 s.
All other measurement parameters were as for the COSY
spectra.
2-Amino-6-methylpyrimidin-4(3H)-one (1)
Starting material; Aldrich, 98 %, m.p. > 300 oC. Additional
data for 2-amino-6-methylpyrimidin-4(3H)-one (1): Rf = 0.12
(EtOAc/MeOH = 3:1); UV (MeOH): lmax/nm: 206, 222, 284,
log e/dm3 mol–1 cm–1: 4.26, 4.27, 4.20; 1H NMR (DMSO-
-d6) d/ppm: 11.35 (br s, 1H, 3-NH), 6.93 (br s, 2H, 2-NH2),
5.41 (s, 1H, H-5), 1.99 (s, 3H, CH3); 13C NMR (DMSO-d6)
d/ppm: 163.76 (s, C-4), 155.53 (s, C-6 probably with C-2),
100.30 (d, C-5), 22.98 (q, CH3).
2-Amino-6-methyl-5-nitropyrimidin-4(3H)-one (2)
2-Amino-6-methyl-5-nitropyrimidin-4(3H)-one (2) was syn-
thesized following the Pankiewicz procedure.12 A mixture
of nitric acid (5.3 mL), conc. sulfuric acid (5.3 mL) and 2-
amino-6-methylpyrimidin-4(3H)-one (1) (1.78 g, 98 %, 14.2
mmol) gave 2 (1.75 g, 72 %) as light brown crystals.
Additional data for 2-amino-6-methyl-5-nitropyrimidin-
4(H)-one (2): m.p. 280 °C decom; Rf = 0.22 (CH2Cl2/MeOH
= 9:1); UV (MeOH): lmax/nm: 203, 296, 326, log e/dm3
mol–1 cm–1: 3.99, 3.65, 3.52; IR (KBr) nmax/cm–1: 3427 (s),
3304 (s), 3177 (s), 3167 (s), 2760 (m), 1675 (s), 1609 (s),
1567 (s), 1499 (s), 1465 (s), 1417 (s), 1352 (s), 1234 (m),
1094 (m), 1009 (w), 782 (m); 1H NMR (DMSO-d6) d/ppm:
11.63 (s, 1H, 3-NH), 6.5–8.5 (br s, 2H, 2-NH2), 2.26 (s, 3H,
CH3); 13C NMR (DMSO-d6) d/ppm: 164.84 (s, C-4), 155.78
(s, C-2), 155.41 (s, C-6), 128.98 (s, C-5), 22.67 (q, CH3).
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2-(N-Dimethylaminomethylene)amino-6-(2-dimethyl-
aminovinyl)-3-methyl-5-nitropyrimidin-4-one (3)
This reaction was performed following the Furneaux and Ty-
ler procedure for preparation of 2-(N-dimethylaminome-
thylene)amino-6-(2-dimethylaminovinyl)-5-nitropyrimidin-
4-one.13 A mixture of 2-amino-6-methyl-5-nitropyrimi-
din-4(3H)-one (2) (1 g, 5.88 mmol) with dry DMF (12.5 mL)
and DMF-dimethylacetal (3.75 mL, 35 mmol) was stirred
at 100 °C for 24 h and then cooled. Acetone (25 mL) was
added, and the mixture was filtered and washed with ace-
tone, affording 2-(N-dimethylaminomethylene)amino-6-(2-
dimethylaminovinyl)-3-methyl-5-nitropyrimidin-4-one (3)
as an orange solid (1.1 g, 64 %): m.p. 196–198 °C; Rf = 0.64
(EtOAc/MeOH = 3:1); UV (MeOH): lmax/nm: 268, 331, 416,
log e/dm3 mol–1 cm–1: 3.97, 4.45, 3.94; IR (KBr) nmax/cm–1:
3448 (w), 2925 (w), 1671 (s), 1629 (s, sh), 1611 (s), 1535
(s), 1511 (s), 1485 (m), 1398 (m), 1384 (m), 1333 (w), 1111
(m), 1055 (s); 1H NMR (DMSO-d6) d/ppm: 8.83 (s, 1H,
CH=N), 8.13 (d, 1H, J = 12 Hz, NHC=CH), 5.37 (d, 1H,
J = 12 Hz, NHC=CH), 3.35 (s, 3H, 3-N–CH3); 3.26 (s, 3H,
N-CH3), 3.16 (br s, 3H, N–CH3), 3.10 (s, 3H, N–CH3), 2.85
(br s, 3H, N–CH3); 13C NMR (DMSO-d6) d/ppm: 159.79
(d, HC=N), 157.04 (s, C-4), 156.40 (s, C-2 or C-6), 156.10
(s, C-6 or C-2), 153.36(d, NCH=CH), 133.06 (s, C-5), 88.16
(d, CH=CHN), 41.53 (q, N–CH3), 39.15 (q, N–CH3), 29.31
(q, 3-N–CH3).
1-Methyl-9-deazaguanine AG-19-K1 and
1,7-dimethyl-9-deazaguanine AG-3
A mixture of 2-(N-dimethylaminomethylene)amino-6-(2-
dimethylaminovinyl)-3-methyl-5-nitropyrimidin-4-one (3)
(2.54 g, 8.63 mmol) and sodium dithionite (5.69 g, 85 %) in
water (25 mL) was heated under reflux for 2 h. The suspen-
sion was hot filtered and the residue was purified by silica
gel column chromatography (CH2Cl2/MeOH = 3:1) to yield
0.624 g (45 %) of 2-amino-3-methyl-3H-pyrrolo[3,2-d]py-
rimidin-4(5H)-one (AG-19-K1) and 0.098 g (6 %) of 2-
amino-3,5-dimethyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one
(AG-3) as white crystals.
2-Amino-3-methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (AG-
19-K1): m.p. 252–255 °C; Rf = 0.67 (EtOAc/MeOH = 3:1);
UV (EtOH): lmax/nm: 231, 256, 290, log e/dm3 mol–1
cm–1: 4.39, 3.91, 3.85; IR (KBr) nmax/cm–1: 3452 (s), 3269
(br s), 1686 (s), 1634 (s), 1546 (s), 1419 (m), 1375 (m),
1299 (m), 1333 (w), 1215 (m), 1167 (s) 1055 (s); 1H NMR
(DMSO-d6) d/ppm: 11.44 (br s, 1H, NH-7), 7.15 (t, 1H, J =
2.9 Hz, H-8), 6.31 (br s, 2H, NH2), 5.94 (t, 1H, J = 2.3 Hz,
H-9), 3.35 (s, 3H, N-1 CH3); 13C NMR (DMSO-d6) d/ppm:
153.93 (s, C-6), 151.22 (s, C-2), 144.60 (s, C-4), 127.37 (d,
C-8), 112.01 (s, C-5), 100.08 (d, C-9) 27.73 (q, 1-N CH3).
COSY spectra: H-8 « H-9, N-7 « H-8, N-7 « H-9;
NOESY spectra: H-8« H-9, N-7« H-8, N-7« H-9 and
NH2 « 1-N–CH3.
2-Amino-3,5-dimethyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one
(AG-3): m.p. 235–238 °C; Rf = 0.41 (EtOAc/MeOH = 3:1);
UV (EtOH): lmax/nm: 230, 257, 291, log e/dm3 mol–1 cm–1:
4.25, 3.85, 3.72; IR (KBr) nmax/cm–1: 3485 (m), 3383 (s),
3251 (w) 1678 (s), 1636 (s), 1560 (s), 1469 (w), 1426 (w),
1393 (w), 1363 (w), 1287 (s), 1239 (m), 1196 (m), 1143 (m),
1056 (s); 1H NMR (DMSO-d6) d/ppm: 7.43 (d, 1H, J = 3.1
Hz, H-8), 6.41 (br s, 2H, NH2), 5.86 (d, 1H, J = 3.1 Hz,
H-9), 3.35 (s, 6H, N-1 and N-7–CH3); 13C NMR (DMSO-d6)
d/ppm: 152.70 (s, C-6 or C-2), 152.04 (s, C-2 or C-6),
147.62 (s, C-4), 131.11 (d, C-8), 110.72 (s, C-5), 98.90 (d,
C-9) 27.92 (q, 1-N and 7-N–CH3).
COSY spectra: H-8 « H-9; NOESY spectra: H-8 «
H-9, H-8 « 7-N–CH3.
In vitro Study
– Inhibition of PNP in vitro (without cells)
Inhibition properties of 9-deazaguanine and its derivatives
were determined as described3 earlier on calf spleen PNP,
with 7-methylguanosine (7-MG) as variable substrate,14
and at two concentrations of the co-substrate phosphate: 50
mmol dm–3 (saturating concentration) and 1 mmol dm–3,
which is supposed to be close to the concentration in cells.
Experiments were conducted at 25 °C in 50 mmol dm–3 He-
pes buffer, pH = 7.0, by the initial velocity method using
spectrophotometric assay (lobs = 260 nm).14 In all kinetic
experiments, the concentration of 9-DG was determined
spectrophotometrically on the basis of the extinction coef-
ficient for the neutral ionic form of the compound (present
in the pH range 7–9): e (266 nm) = 6 600 dm–3 mol–1 cm–1.
– Chemicals
Media, RPMI-1640 and DMEM with 10 % heat inactivated
fetal bovine serum (FBS), penicillin and streptomycin, and
trypsine-EDTA were purchased from the Institute of Immu-
nology Inc. (Zagreb, Croatia); 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) was purchas-
ed from Merck (Darmstadt, Germany, EU) and dimethylsulf-
oxyde (DMSO) was purchased from Eurobio (France, EU).
Superscript II reverse transcriptase was purchased from In-
vitrogen (UK, EU), and oligo(dT)15 and dNTP mix from
Roche Molecular Diagnostics (Germany, EU). Glutamine,
Tri-reagent, 7-methylgunosine, calf spleen purine nucleo-
side phosphorylase and all other chemicals were obtained
from Sigma Chem. Co. (St. Louis, USA). The enzyme ob-
tained as suspension in ammonium sulphate was desalted as
previously described.3
– Cell Culture
Four solid tumor cell lines: SW620 (cells from lymph node
metastasis of colon adenocarcinoma), HT-29 (colon carci-
noma), AGS (gastric adenocarcinoma) and HeLa (cervical
carcinoma) and five leukemia cell lines: HL-60 (human acute
myeloid leukemia), JURKAT (human T-cell leukemia), K562
(human chronic myeloid leukemia in blast crisis), RAJI
(Burkitt lymphoma) and MOLT-4 (human T-cell leukemia)
were used in the study.
Solid tumor cells were grown as a monolayer in DMEM.
Leukemia cells were grown in suspension, in RPMI 1640.
DMEM and RPMI 1640 were supplemented with 10 %
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fetal bovine serum, 2 mmol dm–3 glutamine, 100 U/mL pe-
nicillin (≈ 60 mg/mL) and 100 µg/mL streptomycin. All tested
cell lines were grown at 37 °C in a humidified atmosphere
of 95 % air and 5 % CO2. Trypan blue dye exclusion me-
thod was used to assess cell viability.
– Cell Proliferation Assay
Cells were plated into 96-well plates at concentrations of
2  104 cells per mL for solid tumor cells and 1  105 cells
per mL for leukemia cells. All cell lines were treated with
investigated compounds in a concentration range 10–3–10–6
mol dm–3 and incubated at 37 °C for 72 h. Control cells
were grown in the same conditions but without addition of
test compounds. Cytotoxic effects of 9-DG derivatives on
cell growth were measured using the MTT assay.15 After 3
days of incubation, MTT was added to each well and
incubated for the subsequent 4 h. Precipitate of solid tumor
cells was dissolved in DMSO and that from leukemia cell
in 10 % SDS with 0.01 mol dm–3 HCl. The plate were scan-
ned using an Elisa reader (Stat Fax 2100, Pharmacia Bio-
tech) to measure the extracted dye at 570 nm. All experi-
ments were performed at least three times, with three wells
for each concentration of tested compounds. The effect on
tumor cells growth of various concentrations of 9-DG de-
rivatives was calculated as:
Cells growth / % =
(A Blank)
(B Blank)
−
− ⋅100 (1)
A represents the absorbance of cells remaining after treat-
ment with tested substances and B is the absorbance of cells
without drug stimulation. Blank represents the absorbance
of media without cells; for solid tumor cells media was MTT
and DMSO, while for leukemia cells media was MTT, 10 %
SDS and 0.01 mol dm–3 HCl.
– Extraction of mRNA and Preparation of cDNA and
Purine Nucleoside Phosphorylase (PNP) Gene
Expression
Three leukemia cell lines (RAJI, MOLT-4 and HL-60) were
treated with 10–3 mol dm–3 9-DG and AG-19-K1 for 6, 12 and
24 h. The mRNA from 106 cells was isolated by Tri-reagent.
Target RNA was reverse transcribed using oligo(dT)15, dNTP
mix, and sterile distilled H2O added to the total RNA and
the resulting solution was annealed at 65 °C for 5 min. Then,
the 5X First-Strand Buffer and DTT were added and the
reaction mixture was incubated at 42 °C for 2 minutes. In the
end, the reverse transcriptase was added and the mixture
was incubated at 42 °C for 50 min followed by incubation
at 70 °C for 15 minutes. cDNA for PNP gene was amplified
using Progene Thermal Cycler (Techne Cambridge Ltd.,
UK) with primers 5'-ACACTGCAGAATGGCTTCTG-3'
from nucleotides 144 to 163 (sense primer in exon 2) and
5'-GGTACCCTTCATACATGTGG- 3' from nucleotides 383
and 364 (antisense primer in exon 3).16,17 The amplification
primers used were: GAPDH 5'- CCA TCA ATG ACC CCT
TCA TTG ACC- 3' sense, 5'- GAA GGC CAT GCC
AGT GAG CTT CC- 3' antisense; PNP Standard PCR con-
ditions were applied:18 denaturation at 94 °C, 60 s; anneal-
ing at 51 °C, 120 s; extension at 72 °C, 3 min; 28 cycles
followed by one cycle with 7-minutes extension.
As an internal reference gene was used gene for glyce-
aldehyde-3-phosphate dehydrogenase (GAPDH). cDNA for
GAPDH gene was amplified with primers 5'- CCA TCA
ATG ACC CCT TCA TTG ACC- 3' (sense primer) and 5'-
GAA GGC CAT GCC AGT GAG CTT CC- 3' (antisense
primer).19 The PCR conditions were 95 °C, 68 °C, and
72 °C for 30, 90 and 60 seconds, respectively. Products of
the PCR reaction were separated by 1 % agarose gel elec-
trophoresis. The intensity of the bands was analyzed using
ImageQuantTL software (Pharmacia Biotech, Sweden) and
normalized to internal reference gene GAPDH. Three inde-
pendent experiments were performed. The effects of 9-DG
and 9-DG derivatives on GAPDH gene expression was not
significant during all tested period of exposure, indicating
that GAPDH could be used as a stable housekeeping gene
in this experiment.20
– Statistical Analysis
The Kolmogorov-Smirnov test, a normality distribution test,
was applied. The differences between groups were assessed
by a non-parametric Kruskal-Wallis test (p<0.05). Statisti-
cal analyses were performed with STATISTICATM software
(version 7.0). Data are presented as mean values ± SD of
three separate experiments.
RESULTS
Two synthetic routes were chosen for the synthesis of de-
azaguanine 9-DG (Scheme 1). In the first route,13 2-ami-
no-6-methyl-5-nitropyrimidin-4(3H)-one (2) was treated
with DMF-dimethylacetal (amount ratio, n(2) / n(DMF-
dimethylacetal) = 1:6) and in our hands gave N-3 methyl
substituted intermediate 2-(N-dimethylaminomethyle-
ne)amino-6-(2-dimethylaminovinyl)-3-methyl-5-nitropy
rimidin-4-one (3) as the sole product (73 % yield). Di-
thionite reduction of this product 3 afforded N-methyl
derivatives; 1-methyl-9-dezaguanine AG-19-K1 as the
main product in 45 % yield and 1,7-dimethyl-9-deaza-
guanine AG-3 (6 % yield).
The second route21 for the 9-DG synthesis involves
reaction of 2-amino-6-methyl-5-nitropyrimidin-4(3H)-
one (2) with DMF-dimethylacetal (amount ratio, n(2) /
n(DMF-dimethylacetal) = 1:2.5) and use of the benzyl-
oxymethyl group to protect the N-3 position of 2-
(N-dimethylaminomethylene)amino-6-methyl-5-nitropy-
rimidin-4(3H)-one (4). Treatment of 4 with benzyl chlo-
romethyl ether in DMF in the presence of 1,8-diazabi-
cyclo[5,4,0]undec-7-ene (DBU) at room temperature, fol-
lowed by condensation with DMF-dimethylacetal in DMF
gave compound 5. Subsequent reductive cyclization of 5
produced the protected 9-deazaguanine derivative 6. The
removal of the protecting group by catalytic hydrogena-
tion gave the desired 9-DG.
Results of the antiproliferative activity of AG-19-K1,
AG-3 and 9-DG on several leukemia and solid tumor
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cell lines are shown in Figure 1. Investigated compounds
show moderate antiproliferative activity towards the ex-
amined cell lines. Compound AG-19-K1 at a concentra-
tion of 10–3 mol dm–3 has the strongest inhibitory effect
on the tumor cells growth when compared to the two other
compounds tested. AG-19-K1 (10–3 mol dm–3) inhibits
growth of leukemia (JURKAT, K562) and gastric adeno-
carcinoma (AGS) cell lines by approximately 80 % and
all other tested cell lines by about 50 % (Figure 1a). At a
concentration of 10–4 mol dm–3, AG-19-K1 inhibits pro-
liferation of SW620 and HT-29 cells in a range of 15–25 %
and has no influence on the proliferation of other treated
cell lines.
Compound AG-3 displays similar moderate antipro-
liferative capacity (Figure 1b). At a concentration of 10–3
mol dm–3, it inhibits cell proliferation of JURKAT and
K562 cells by approximately 55 %. Inhibition effect was
30–45 % for other cell lines, i.e., SW620, RAJI, HT-29,
HeLa, and AGS cells. At a concentration of 10–4 mol dm–3,
AG-3 slightly inhibits growth of investigated cell lines.
Compound 9-DG, in a concentration of 10–3 mol dm–3
also inhibits cell growth in a range of 35–47 % in the
case of solid tumor cell lines and by 15–55 % in the case
of leukemia cells (Figure 1c). 9-DG applied in lower
concentrations has no influence on tumor cells growth.
Investigation of the PNP gene expression after 6, 12
and 24 h exposure of leukemia cells to 10–3 mol dm–3
AG-19-K1 and 9-DG showed a significant decrease in a
time-dependent manner (Figure 2). Compared to the
controls, AG-19-K1 evokes drop in PNP expression of
MOLT-4 cells by 60 %, 70 %, and 55 % after 6, 12, and
24 hours of treatment respectively. Under the same con-
ditions, 9-DG significantly affects PNP expression after
6 h of treatment (70 %), but after 12 and 24 h of expo-
sure, PNP mRNA level begin to rise. The investigated
gene expression in treated HL-60 was quite changed com-
pared to the controls. In comparison to the previously
described treated cell lines, AG-19-K1 induces the best
inhibition effect on the PNP gene expression in RAJI
cells (81 %) after 6 h of treatment. 9-DG also leads to a
reduction in the PNP gene expression (80 %) after 6 h of
treatment in the same cells, but after 12 and 24 h of ex-
posure, negligible inhibitory effects were observed.
Inhibition of mammalian PNP by 9-deazaguanine and
its two derivatives AG-19-K1 and AG-3 was determined
using calf spleen enzyme and 7-methylgunosine as va-
riable substrate at two concentrations, 50 mmol dm–3 and
1 mmol dm–3 of the co-substrate, phosphate. Trimeric
PNPs are known for their non-Michaelis kinetics, espe-
cially when the concentration of natural nucleoside sub-
strates (inosine, guanosine) or phosphate is varied.2,3 We
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Scheme 1. Synthesis of 9-deazaguanine derivatives (double arrows indicate the intramolecular NOE effects).
have previously shown that, by contrast, kinetics of 7-
methylguanosine may be in some cases analyzed using
the Michaelis-Menten model.3 However, data shown in
Figure 3 clearly indicate that when 9-DG is used as an
inhibitor, the inhibition constant cannot be determined by
standard kinetic approaches and procedures (i.e., slope of
the Lineveawer-Burk plot, line crossing of the Dixon plot,
etc.) derived for the Michaelis kinetics. As shown in
Figure 3, lines on 1/v vs. 1/c plot and those on 1/v vs. [I]
plot do not cross at one point. It should be underlined
that this does not result from experimental errors but from
the kinetic properties of the enzymatic reaction catalyz-
ed by trimeric PNPs.
Therefore, instead of the inhibition constant, parame-
ter IC50 was determined on the basis of these data, since
such analysis is not based on the Michaelis-Menten ki-
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Figure 1. Effects of AG-19-K1 (a), AG-3 (b), and 9-DG (c) on the growth of different solid tumor and leukemia cells. Exponentially
growing cells were treated with different concentrations of investigated compounds during a 72 h period. Cytotoxicity was analyzed using
the MTT survival assay. All experiments were performed at least three times. Tumor cells growth was calculated by Eq. (1). Statistically
significant differences from control (P ≤0.05) are marked with asterisks.
netic equation. Results of such analysis can be summa-
rized as follows: 9-deazaguanine inhibits calf spleen PNP
with IC50 of about (2.3 ± 0.5) mmol dm–3 at 1 mmol dm–3
phosphate and (12 ± 3) mmol dm–3 at 50 mmol dm–3 phos-
phate concentration. Two 9-deazaguanine derivatives,
AG-19-K1 and AG-3, both with substituents at position
N-1 of the purine base, are inactive vs. calf spleen PNP
in the concentration of 75 mmol dm–3 at 1 mmol dm–3
phosphate (data not shown).
DISCUSSION
As part of our ongoing program directed towards the syn-
thesis of some novel nucleosides22–27 with potentially
useful biological activity, we were exploring the synthe-
sis of 3H,5H-pyrrolo[3,2-d]pyrimidines (9-deazaguanine
derivatives).
There are relatively few routes to the pyrrolo[3,2-d]-
pyrimidine ring system, and the most commonly used ap-
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Figure 2. Effects of 9-DG and AG-19-K1 on PNP gene expression. (a) Agarose gel electrophoresis of PCR products. Total mRNA was
obtained from three different leukemia cell lines (MOLT-4, HL-60 and RAJI) after treatment by tested compounds (AG-19-K1 and 9-DG) at
concentration of 10–3 mol dm–3 and from control (nontreated) cells. After amplification with specific primers, PCR products of cDNA were
analyzed using ImageQuantTL software. (b) Results of PNP gene expression in treated cells after quantification with respect to the PNP gene
expression in control cells. PNP gene expression was normalized with expression of housekeeping gene glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). Statistically significant differences from control (P ≤0.05) are marked with asterisks.
Figure 3. Inhibition of calf spleen PNP by 9-DG shown in the form of the Lineveawer-Burk plot (left panel) and the Dixon plot (right
panel). Experiments were conducted at 25 °C in 50 mmol dm–3 Hepes buffer, pH = 7.0, by the continuous spectrophotometric method14
(lobs = 260 nm) with 7-methylguanosine (7-MG) as substrate and at constant, 1 mmol dm–3 phosphate concentration.
proach starts from pyrimidines with appropriate functional
groups at the C-5 and C-6 positions to allow elaboration
of the pyrrole ring (Scheme 1). Otherwise, the pyrimi-
dine ring can be constructed onto a substituted pyrrole.28
Our synthetic plan was to synthesize 9-DG on a multi-
gram scale and we explored an improved protocol13 which,
however, in our hands did not lead to the expected com-
pound. Instead, methylation on the heterocycle was ob-
served, as also reported by other researchers.29 The N-
methylation as well as formation of imine was observed
when 2-amino-6-methyl-5-nitropyrimidin-4(3H)-one (2)
was treated with DMF-dimethylacetal (amount ratio, n(2) /
n(DMF-dimethylacetal) = 1:6), Scheme 1. 2-(N-Dimethyl-
aminomethylene)amino-6-(2-dimethylaminovinyl)-3-me
thyl-5-nitropyrimidin-4-one (3) was isolated as the sole
product. In 1H as well as 13C NMR spectra of 3, methyl
group at position N-3 was identified at d = 3.35 ppm (s,
3H) and d = 29.31 ppm (q), respectively. Dithionite re-
duction of product 3 afforded N-methyl derivatives; 1-
methyl-9-dezaguanine AG-19-K1 as the main product in
45 % yield and 1,7-dimethyl-9-deazaguanine AG-3 (6 %
yield). The structure of 9-deazaguanine derivatives sub-
stituted with methyl group was assigned on the basis of
1H NMR spectra. The N-1–H proton signal at 10.44 ppm
(characteristic of 9-DG in DMSO) was not observed in
the case of AG-19-K1, and in the case of AG-3, the
N-1–H proton signal at 10.44 ppm and also the N-7–H
proton signal at 11.42 ppm (DMSO) were missing. This
assignment was supported by the 13C NMR spectra (car-
bon signal for CH3- group at 27 ppm, quartet) and 2D
NMR NOESY spectra (in Scheme 1 double arrows indi-
cate the intramolecular NOE effects). In the NOESY ex-
periment with AG-19-K1, strong NOE interactions be-
tween H-8 (d = 7.15 ppm) and NH-7 (d = 11.44 ppm),
and NH2-2 (d = 6.31 ppm) and CH3-1 (d = 3.35 ppm)
support the N-1 metylation of the 9-deazaguanine base.
The NOESY spectrum of AG-3 showed strong NOE in-
teractions between H-8 (d = 7.43 ppm) and CH3-7 (d =
3.35 ppm), which together with the CH3-1 and CH3-7
protons signal at d = 3.35 ppm (s, 6H in DMSO) in 1H
NMR spectra support the N-1 and N-7 metylation of the
9-deazaguanine base.
The most versatile approach for the synthesis of 9-
deazaguanine (9-DG) was described by Sartorelli and
co-workers,21 wherein the 9-DG was generated in five
steps after reductive cyclization of the key-intermediate
5 (Scheme 1). Following this procedure, we have prepar-
ed 9-DG in the overall yield of 50 %.
9-DG and its two methyl derivatives were tested as
potential inhibitors of mammalian PNP. Results of the in
vitro study performed on calf spleen PNP are fully in line
with all that we know about the active site of calf spleen
enzyme and other trimeric PNPs. Absence of inhibition
observed with 1-methyl-9-deazaguanine AG-19-K1 and
1,7-dimethyl-9-deazaguanine AG-3 results from the fact
that the hydrogen at position N-1–H defines the specifi-
city of the enzyme.2,30 In inhibition studies with calf spleen
PNP, errors are very big since the inhibitor data cannot
be properly analyzed by a pure competitive, uncompe-
titive, noncompetitive or even mixed inhibitor model
since, as we have shown earlier, calf spleen PNP kinetics
does not obey the Michaelis-Menten model.2,3,31 There-
fore, a more reliable parameter characterizing interactions
of inhibitors with calf spleen and other trimeric PNPs is
a dissociation constant. For the complex 9-deazaguani-
ne/calf spleen PNP, this was obtained earlier form the
steady-state fluorescence titration experiments and is
(0.17 ± 0.02) µmol dm–3 at pH = 7.0 in the absence of
phosphate.32
The antiproliferative activity of 9-DG and its methyl
derivatives AG-19-K1 and AG-3 was tested against a
panel of tumor cell lines. Results of our study show that
these compounds display moderate antiproliferative ef-
fects on investigated tumor cells. There is no significant
difference in their cell growth inhibition activity between
the treated leukemia and solid tumor cell lines. In com-
parison to the 9-DG, methylated derivatives AG-19-K1
and AG-3 more potently decrease treated tumor cells
growth, at a relatively high dose (10–3 mol dm–3). The
maximum of growth inhibitory efficacy (80 %) on the
growth of K562, JURKAT and AGS is achieved using
10–3 mol dm–3 AG-19-K1. AG-3, the compound with two
methyl groups, maximally inhibits cell proliferation of
K562 and JURKAT cells by 55 %, and AGS and HT-29
by 45 %. Recent studies on nucleosides with 9-DG agly-
cone showed their positive antiproliferative effects on tu-
mor cells and significant inhibitory potential on catalytic
activity of PNP.33,34 In comparison with these results, sub-
stances investigated in this study do not display pronounc-
ed antitumor effects. Despite the potent PNP inhibitory
potential of 9-DG, no differences were observed between
the effects on the growth of tumor cells with increased
PNP activity (such as human adult T-cell leukemia and
colon carcinoma cells) and tumor cells, where PNP en-
zyme activity is unchanged.7,35,36 On the other hand, the
two methyl derivatives AG-19-K1 and AG-3 (both with
substituents at position N-1 of the purine base, which
makes these analogues unable to form hydrogen bond via
N-1–H position with PNP), were inactive vs. calf spleen
PNP but they displayed better cytotoxic activity against
all treated tumor cells compared to 9-DG.
While some purine nucleoside analogues down-regu-
late expression of PNP gene37,38 and, to our knowledge,
the effect of 9-DG on PNP gene expression has not yet
been investigated, the influence of 9-DG and AG-19-K1
on modulation of PNP gene expression was also tested.
In comparison with the other two treated cell lines, AG-
19-K1 (after 6 and 12 h of treatment) showed the strongest
and prolonged inhibition effects on PNP gene expression
in human T cell leukemia (MOLT-4) cells and affected
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their growth by approximately 50 %. After 6 h of treat-
ment with 9-DG, expression of the target gene in MOLT-4
and RAJI cell lines decreased by approximately 50 %. In
comparison with 9-DG, regardless of the exposure time,
AG-19-K1 caused stronger inhibition effects on the PNP
gene expression in all tested cell lines, except in RAJI
cells after 24 h of exposure. The results of our study show
that the tested substances modulate PNP gene expres-
sion but further research is needed for a better insight.
In conclusion, the presented 9-deazaguanine and its
methyl derivatives, synthesized as pools for the future syn-
thesis of novel purine nucleosides (9-deazaguanine deri-
vatives), slightly affect the growth of solid tumor and
leukemia cells and significantly modulate PNP gene ex-
pression in leukemia cells. 9-deazaguanine is a potent in-
hibitor of mammalian PNP.
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SA@ETAK
9-deazagvanin i njegovi metilni derivati: Sinteza, protutumorsko djelovanje i u~inci
na ekspresiju gena za purin-nukleozid-fosforilazu
Mirjana Suver, Biserka @ini}, Tomislav Portada, Agnieszka Bzowska i Ljubica Glava{-Obrovac
Sintetizirani su 9-deazagvanin (9-DG), 1-metil-9-deazagvanin (AG-19-K1) i 1,7-dimetil-9-deazagvanin
(AG-3). Ispitivane su njihove antiproliferativne sposobnosti na pet leukemijskih i 4 stani~ne linije dobivene iz
~vrstih tumora, te njihov inhibicijski potencijal za purin-nukleozid-fosforilazu (PNP) iz slezene teleta. Sinteza
9-DG uklju~uje reakciju 2-amino-6-metil-5-nitropirimidin-4(3H)-ona (2) s DMF-dimetilacetalom (mno`inski omjer,
n(2) / n(DMF-dimetilacetal) = 1 : 6) i za{titu N-3 polo`aja 2-(N-dimetilaminometilen)amino-6-metil-5-nitro-
pirimidin-4(3H)-ona (4) s benziloksimetilnom skupinom. Reakcijom spoja 2 s DMF-dimetilacetalom (mno`inski
omjer, n(2) / n(DMF-dimetilacetal) = 1 : 2,5) nastaje (N-3)-metilni spoj 3. Ditionitna redukcija tog produkta
daje N-metilne derivate AG-19-K1 i AG-3. AG-19-K1 i AG-3 u koncentraciji 75 ìmol dm–3 nisu inhibirali
PNP. Citotoksi~ni u~inci derivata 9-DG na rast tumorskih stanica ispitani su MTT-testom. Istra`ivani spojevi
pokazali su slabe u~inke na rast tumorskih stanica. Rezultati pokazuju da AG-19-K1 u koncentraciji od 10–3
mol dm–3 inhibira rast stanica JURKAT, K562 i AGS u prosjeku za 80 %. U istoj koncentraciji, AG-3 i 9-DG
inhibiraju za 40-50 % stani~nu proliferaciju svih ispitanih stani~nih linija MOLT-4 i HL-60. U ovisnosti o vre-
menu izlaganja, u leukemijskim stanicama izlo`enim djelovanju AG-19-K1 i 9-DG dolazi do zna~ajnih pro-
mjena u ekspresiji gena PNP.
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